Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)

NCT03257033 Phase 3 RECRUITING

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Details

Lead sponsor	RenovoRx
Phase	Phase 3
Status	RECRUITING
Enrolment	190
Start date	2018-03-12
Completion	2026-09

Conditions

• Locally Advanced Pancreatic Cancer

Interventions

• Gemcitabine
• nab-paclitaxel
• RenovoCath

Primary outcomes

• Overall Survival — Up to Five Years
  OS from time of randomization will be calculated using the Kaplan-Meier method and compared between the test and control groups using the stratified Wilcoxin Test

Countries

United States, Belgium